Caribou Biosciences, Inc.

Caribou Biosciences, Inc. Stock Forecast & Price Prediction

Live Caribou Biosciences, Inc. Stock (CRBU) Price
$2.13

9

Ratings

  • Buy 7
  • Hold 2
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$2.13

P/E Ratio

-1.54

Volume Traded Today

$1.1M

Dividend

Dividends not available for CRBU

52 Week High/low

8.33/1.50

Caribou Biosciences, Inc. Market Cap

$196.5M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $CRBU ๐Ÿ›‘

Before you buy CRBU you'll want to see this list of ten stocks that have huge potential. Want to see if CRBU made the cut? Enter your email below

CRBU Summary

Based on ratings from 9 stock analysts, the Caribou Biosciences, Inc. stock price is expected to increase by 486.85% in 12 months. This is calculated by using the average 12-month stock price forecast for Caribou Biosciences, Inc.. The lowest target is $3 and the highest is $26. Please note analyst price targets are not guaranteed and could be missed completely.

CRBU Analyst Ratings

Caribou Biosciences, Inc. has a total of 9 Wall St Analyst ratings. There are 7 buy ratings, 2 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Caribou Biosciences, Inc. will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

CRBU stock forecast by analyst

These are the latest 20 analyst ratings of CRBU.

Analyst/Firm

Rating

Price Target

Change

Date

Yigal Nochomovitz
Citigroup

Buy

$6

Maintains

Nov 26, 2024
Robert Burns
HC Wainwright & Co.

Buy

$9

Reiterates

Nov 15, 2024
Robert Burns
HC Wainwright & Co.

Buy

$9

Reiterates

Sep 3, 2024
Robert Burns
HC Wainwright & Co.

Buy

$9

Reiterates

Aug 14, 2024
Luca Issi
RBC Capital

Outperform

$14

Reiterates

Aug 7, 2024
Robert Burns
HC Wainwright & Co.

Buy

$9

Reiterates

Jul 17, 2024
Robert Burns
HC Wainwright & Co.

Buy

$9

Maintains

Jun 4, 2024
Asthika Goonewardene
Truist Securities

Buy

$19

Maintains

May 16, 2024
Robert Burns
HC Wainwright & Co.

Buy

$24

Reiterates

May 13, 2024
Robert Burns
HC Wainwright & Co.

Buy

$24

Maintains

Mar 19, 2024
Luca Issi
RBC Capital

Outperform

$19

Reiterates

Mar 12, 2024
Rick Bienkowski
Cantor Fitzgerald

Neutral


Initiates

Nov 8, 2023
Robert Burns
HC Wainwright & Co.

Buy

$23

Maintains

Jul 26, 2023

Truist Securities

Buy


Reiterates

Jul 14, 2023
Asthika Goonewardene
Truist Securities

Buy

$23

Initiates

Jul 11, 2023
Robert Burns
HC Wainwright & Co.

Buy

$25

Maintains

May 10, 2023
Robert Burns
HC Wainwright & Co.

Buy

$26

Maintains

Mar 14, 2023
Mark Breidenbach
Oppenheimer

Outperform

$32

Maintains

Mar 10, 2023
Luca Issi
RBC Capital

Outperform

$19

Reiterates

Mar 10, 2023
Yigal Nochomovitz
Citigroup

Buy

$38

Maintains

Aug 29, 2022

CRBU Company Information

What They Do: Develops genome-edited cell therapies for cancer.

Business Model: The company operates as a clinical-stage biopharmaceutical entity, focusing on the development of allogeneic cell therapies utilizing genome editing technology. It generates revenue primarily through partnerships, licensing agreements, and potential future sales of its innovative cell therapy products aimed at treating various hematologic malignancies.

Other Information: Caribou Biosciences, Inc. is in the trial phase for multiple product candidates, including CB-010 for B cell non-Hodgkin lymphoma, CB-011 for multiple myeloma, and CB-012 for acute myeloid leukemia. Founded in 2011 and based in Berkeley, California, the company is positioned in a rapidly evolving market with significant growth potential in the field of cancer therapeutics.
CRBU
Caribou Biosciences, Inc. (CRBU)

When did it IPO

N/A

Staff Count

158

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Dr. Rachel E. Haurwitz Ph.D.

Market Cap

$196.5M

Caribou Biosciences, Inc. (CRBU) Financial Data

In 2023, CRBU generated $34.5M in revenue, which was a increase of 148.91% from the previous year. This can be seen as a signal that CRBU's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$12.4M

Revenue From 2021

$9.6M

-22.35 %
From Previous Year

Revenue From 2022

$13.9M

44.31 %
From Previous Year

Revenue From 2023

$34.5M

148.91 %
From Previous Year
  • Revenue TTM $11.5M
  • Operating Margin TTM -1,666.9%
  • Gross profit TTM $0
  • Return on assets TTM -25.1%
  • Return on equity TTM -43.6%
  • Profit Margin 0.0%
  • Book Value Per Share 3.11%
  • Market capitalisation $196.5M
  • Revenue for 2021 $9.6M
  • Revenue for 2022 $13.9M
  • Revenue for 2023 $34.5M
  • EPS this year (TTM) $-1.66

Caribou Biosciences, Inc. (CRBU) Latest News

News Image

Wed, 20 Nov 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Caribou Biosciences' CEO, Rachel Haurwitz, will participate in upcoming investor conferences, highlighting the company's ongoing engagement with the investment community.

Why It Matters - Rachel Haurwitz's participation in investor conferences can enhance Caribou Biosciences' visibility, potentially attracting new investment and influencing stock performance.

News Image

Mon, 18 Nov 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - A proposed class action settlement has been approved by the U.S. District Court for Northern California for purchasers of Caribou Biosciences, Inc. (NASDAQ: CRBU) common stock.

Why It Matters - The approved class action settlement for Caribou Biosciences may impact stock value and investor sentiment, signaling potential legal risks and financial implications for the company.

News Image

Wed, 06 Nov 2024

Sentiment - NEGATIVE

Source - Zacks Investment Research

Summary - Caribou Biosciences, Inc. (CRBU) reported a quarterly loss of $0.38 per share, better than the expected loss of $0.44, but worse than a $0.12 loss per share a year earlier.

Why It Matters - Caribou Biosciences' smaller-than-expected loss indicates improving performance, which may enhance investor confidence and sentiment towards the stock.

News Image

Mon, 30 Sep 2024

Sentiment - POSITIVE

Source - Seeking Alpha

Summary - Caribou Biosciences (CRBU) is developing allogeneic CAR-T therapies using its chRDNA technology. Its candidate CB-010 is in Phase 1 trials for large B cell lymphoma, showing promising results.

Why It Matters - Caribou Biosciences' advanced chRDNA technology and promising Phase 1 trial results for CB-010 may enhance its competitive edge, impacting stock performance and investment potential in biotech.

News Image

Mon, 19 Aug 2024

Sentiment - NEUTRAL

Source - Accesswire

Summary - Pomerantz LLP is investigating claims for Caribou Biosciences, Inc. (NASDAQ: CRBU) investors. Interested parties can contact Danielle Peyton for details.

Why It Matters - Investors in Caribou Biosciences may face potential legal issues, which could impact stock performance and investor sentiment, highlighting risks associated with the company.

News Image

Mon, 12 Aug 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Caribou Biosciences appointed Dr. Tina Albertson as chief medical officer, bringing 15 years of experience in CAR-T therapies, to lead clinical and regulatory efforts for its programs.

Why It Matters - The appointment of Dr. Albertson strengthens Caribou Biosciences' leadership in CAR-T therapies, potentially enhancing clinical development success and investor confidence in upcoming trials.

...

CRBU Frequently asked questions

The highest forecasted price for CRBU is $26 from Robert Burns at HC Wainwright & Co..

The lowest forecasted price for CRBU is $3 from from

The CRBU analyst ratings consensus are 7 buy ratings, 2 hold ratings, and 0 sell ratings.